Project Determination

# **CBO Survey on Changes in Preparedness and Resources for Support of Biomedical HIV Prevention**

|  |  |
| --- | --- |
| **Project ID:** | 0900f3eb81a71c96 |
| **Project Contact:** | Jones\_Jamal (opy3) |
| **Organization:** | NCHHSTP |
| **Status:** | Pending Clearance |
| **Intended Use:** | Project Determination |
| **Estimated Start Date:** | 10/02/20 |
| **Estimated Completion Date:**  | 05/03/21 |
| **CDC/ATSDR HRPO/IRB Protocol#:**  |  |
| **OMB Control#:**  |  |
|  |  |

|  |
| --- |
| Description |
| Priority |
| Standard |
| Date Needed |
| 12/23/19 |
| Determination Start Date |
| 12/06/19 |
| Description |
| We plan to conduct a survey among clinical and non-clinical community-based organizations (CBO) funded by the CDC and unfunded clinical and non-clinical CBOs. Data collected from this survey will assess provision of Treatment as Prevention (TasP), non-occupational post-exposure prophylaxis (nPEP), and pre-exposure prophylaxis (PrEP). |
| Goals/Purpose |
| The goals of the survey are to assess CBOs awareness of, intentions to provide, and provision of TasP, nPEP, or PrEP. We will also assess changes in awareness and provision of biomedical HIV prevention interventions among these organizations by comparing responses from a newer survey to those of a previous survey (2015) conducted by DHAP’s Health Services Research for Prevention with Negatives Team (HSRPWN). |
| Objective |
| Conduct a survey among clinical and non-clinical CBOs funded by the CDC and unfunded clinical and non-clinical CBOs. Data collected from this survey will be compared to data collected in 2015 to assess differences in awareness, intentions to provide, and provision of TasP, nPEP, or PrEP. This information with help the CDC identify areas for capacity building of CBOs as well as to develop education materials on how CBOs can scale-up their biomedical prevention services. |
| Activities or Tasks |
| New Collection of Information, Data, or Biospecimens |
| Target Population to be Included/Represented |
| Healthcare Personnel: Other-Survey respondents will be representatives of the community-based organizations. |
| Tags/Keywords |
| Surveys and Questionnaires: HIV |
| CDC's Role |
| CDC is the sole institution conducting activity |
| Method Categories |
| Survey |
| Methods |
| Respondents will include organizations engaged in HIV prevention and outreach. 330 respondents (N=330; 175 funded CBOs and 155 unfunded CBOs) will be recruited to complete the survey. Selection, inclusion or sampling of participants: Two sampling strata will be created: A. Clinical and non-clinical CBOs directly funded by CDC. B. Unfunded clinical and non-clinical CBOs who applied for CDC funding. This project will employ a cross-sectional survey design. All CBOs within each of the two strata (mentioned above) will receive phone calls to elicit interest in participating in the survey and to receive the contact information of an organization’s representative to complete the survey on behalf of the organization. Each organization’s representative will be sent an email with a link to the survey website (created with Survey Monkey). The email will instruct the representative on how to complete the survey. Three email reminders will be sent to organizations for those that do not complete the survey to achieve a 50% completion rate. If responses are received from 50% of organizations in each group (A and B), the survey will be closed and responses analyzed. If this response rate is not achieved, phone calls will be made to non-responsive CBOs to elicit participation in the survey. |
| Collection of Info, Data, or Bio specimens |
| All organizations within Strata A and B will be invited to complete the survey. Phone calls will be made to each CBO to elicit interest in participating in the survey and to receive the contact information of the organization’s representative. Each representative nominated from an organization will be sent an email with a link to the survey website (created with Survey Monkey). The email will instruct the recipient on how to complete the survey. Three email reminders will be sent to organizations for those that do not complete the survey to achieve a 50% completion rate. If responses are received from 50% of invited organizations in each group (A and B), the survey will be closed and responses analyzed. If this response rate is not achieved, phone calls will be made to non-responsive CBOs to elicit participation in the survey. |
| Expected Use of Findings/Results and their impact |
| Results from the survey will be presented to CDC staff internally and to public health professionals and other scientists externally (at conferences and other scientific symposia) to inform development of educational materials for CBOs engaged in biomedical HIV prevention activities. The results will also allow CDC staff in DHAP to identify targets for capacity building so that CBOs can efficiently and effectively deliver biomedical HIV prevention tools and treatment. Findings from the survey may also be published in the form of a scientific article within a public health or HIV journal. |
| Will PII be captured? |
| Yes |
| Does CDC have access to the Identifiers |
| Yes |
| Is a certificate or assurance of confidentiality in place or planned? |
| No |
| Is a non-disclosure agreement in place? |
| No |

| ****Funding**** |  |  |  |  |
| --- | --- | --- | --- | --- |
| Funding Type | Funding Title | Funding # | Original Fiscal Year | # of Years of Award |

| ****Institutions**** |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Institution | FWA # | FWA Exp. Date | IRB Title | IRB Exp. Date | Funding # |

| ****Staff**** |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Staff Member | SIQT Exp. Date | Citi Biomedical Exp. Date | Citi Social and Behavioral Exp. Date | Citi Good Clinical Exp. Date | Staff Role | Email | Phone # | Organization/Institution |
| Dawn Smith | 12/04/2021 | 09/29/2021 |  |  | Co-Investigator | dks0@cdc.gov | 404-639-5166 | HSR PREVENTION WITH NEGATIVES TEAM |
| Karen Hoover | 12/26/2021 |  |  |  | Co-Investigator | ffw6@cdc.gov | 404-639-8534 | EPIDEMIOLOGY BRANCH |
| Susan Danner | 12/31/2022 |  |  |  | Co-Investigator | spd1@cdc.gov | 404-639-3 | PROGRAM OPERATIONS TEAM |

|  |  |
| --- | --- |
| ****DMP**** |  |
| ****Proposed Data Collection Start Date**** | **09/01/20** |
| ****Proposed Data Collection End Date**** | **05/03/21** |
| ****Proposed Public Access Level**** | **Public** |
| ****Public Access justification**** | **All PII will be removed before the data are shared. There are no restrictions for access to the survey data and all survey data will be made available to the public.** |
| ****How Access Will Be Provided for Data**** | **Tables containing personally identifying information (PII) (i.e., name and email of the organization's representative as part of recruitment activities) will be collected electronically and stored as a password protected Excel file that is stored on a secure CDC network drive, and only the principal investigator will have access to the file. Electronic survey data will be immediately downloaded from the Survey Monkey server and stored in a CDC CSV file that is password protected and encrypted (even at rest). Any changes to the electronic database are audited by systems controls to identify who made the change, when, and what change was made. We will make survey data available to the public per the CDC’s policy on Public Health Research and Non-research Data Management and Access. Data underlying the conclusions of peer-reviewed scientific publications will be made available in a publicly accessible repository per CDC guidelines and policy.** |
| ****Plans for archival and long-term preservation of the data**** | **The project records, including data, will be archived according to CDC’s Scientific and Research Project Records Control Schedule.** |

| ****Spatiality (Geographic Location)**** |  |  |
| --- | --- | --- |
| Country | State/Province | County/Region |

| ****Determinations**** |
| --- |
| Determination | Justification | Completed | Entered By & Role |
| HSC: Does NOT Require HRPO Review | Research that involves de-identified/unlinkable data or biospecimens, but not involving FDA investigational products | 01/24/20 | Dodson\_Janella R. (jhd7) CIO HSC |
| PRA: PRA does not apply |  | 01/30/20 | Bonds\_Constance (akj8) CTR OMB/PRA Coordinator |